Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: health insurance

Advocates for Arthritis Push for Policy Changes at Annual Event

  |  

The ACR advocates on behalf of the rheumatology community throughout the year, but it’s always especially exciting when patients join our efforts in Washington, D.C. Close to 100 patients, rheumatologists and representatives of the broader interprofessional team traveled to our nation’s capital this week to participate in the ACR’s annual Advocates for Arthritis event. Participants…

Is Concierge Medicine Right for Your Practice?

  |  

It is no surprise to practicing physicians that the healthcare landscape is becoming more and more unpredictable. Because of the volatility surrounding today’s healthcare environment, such as increasing overhead costs and decreasing reimbursement rates, many physicians are asking themselves whether there is a different, more lucrative way to practice medicine. Concierge medicine may just be…

New Research Shows Knee Osteoarthritis Prevalence Is Rising

  |  

Studies highlighting the large numbers of people affected by knee osteoarthritis (OA) point to what clinicians who treat knee OA have been seeing for the past few decades: a substantial increase in the prevalence of knee OA in the U.S. and globally. Roughly 250 million people are affected by knee OA worldwide, and about 14…

Racial Disparities in Rheumatology: What Are We Doing About It?

  |  

The data tell the story. Despite improvements in overall outcomes for common rheumatologic conditions, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), white patients fare better than minority patients, and sometimes substantially better. Even with new biologic therapies that have significantly altered the course of disease for patients with RA, outcomes for minorities…

ACR Advocates for Access to Viscosupplementation for OA

  |  

In several U.S. states, Blue Cross/Blue Shield and other insurers have dropped or are considering dropping coverage of hyaluronic acid injection—or viscosupplementation—for patients with knee osteoarthritis. The decision appears to be based on guidelines published by the American Academy of Orthopaedic Surgeons in 2013, which at that time specified that research had not found hyaluronic…

Anxiety, Depression May Help Predict Outcome of Low Back Pain Treatment

Lorraine L. Janeczko  |  

NEW YORK (New York)—Patients with anxiety and depression may be less satisfied than other patients with their chronic low back pain (CLBP) treatments, new research suggests. “Patients with anxiety/depression symptoms experienced more pain severity and more pain-related functional, social, and emotional disability, and they were less satisfied with care, compared with the other groups,” the…

Phase 3 Trial Results: Blisibimod for Lupus Shows Possible Efficacy

Renée Bacher  |  

A phase 3 clinical trial in which researchers treated lupus patients with blisibimod, a biologic treatment that inhibits B cell activating factor (BAFF), did not meet its primary endpoint, but did demonstrate evidence of possible efficacy. Researcher Joan T. Merrill, MD, a member of the Oklahoma Medical Research Foundation (OMRF) and OMRF professor of medicine…

ACR & NPF Highlight Medicare Access Challenges in Capitol Hill Briefing

  |  

Concerns about how the Trump administration’s ideas to lower drug prices could reduce patient access to medicines led the ACR to speak out on many different fronts. On June 25, at a briefing hosted by the ACR and the National Psoriasis Foundation (NPF), a packed room of Congressional staffers and reporters learned from rheumatologists and…